SCHEMBL6232500

SCHEMBL6232500

COC(=O)c1ccc2c(=O)[nH]sc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
PARP1 P09874 3/20 0.50
LMNA P02545 3/20 0.50
MAPT P10636 2/20 0.50
POLB P06746 1/20 0.50
MAOA P21397 1/20 0.49
KIF11 P52732 1/20 0.47
CSNK2A1 P68400 1/20 0.45
CA1 P00915 3/20 0.45
CA2 P00918 3/20 0.45
CA12 O43570 2/20 0.45
CA7 P43166 2/20 0.45
CA9 Q16790 2/20 0.45
CA14 Q9ULX7 2/20 0.45
XDH P47989 1/20 0.45
KDM4E B2RXH2 2/20 0.44
HPGD P15428 1/20 0.44
HSD17B10 Q99714 1/20 0.44
HDAC1 Q13547 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL92264 0.86 MAPT (0.60) ALDH1A1PARP1LMNAMAPTPOLB
SCHEMBL13875106 0.84 HCRTR1 (0.51) ALDH1A1PARP1LMNAMAPTPOLB
SCHEMBL13939532 0.82 ALDH1A1 (0.45) ALDH1A1PARP1LMNAMAPTPOLB
SCHEMBL6152844 0.80 ALDH1A1 (0.56) ALDH1A1PARP1LMNAMAPTPOLB
SCHEMBL6228576 0.73 MAOA (0.59) ALDH1A1LMNAMAPTPOLBMAOA
SCHEMBL27201497 0.73 HDAC1 (0.49) ALDH1A1PARP1LMNAMAPTKIF11
SCHEMBL10858784 0.73 CHRNA7 (0.46) ALDH1A1PARP1LMNAMAPTKIF11
SCHEMBL79222 0.72 ALDH1A1 (0.50) ALDH1A1LMNAMAPTPOLBMAOA
SCHEMBL11737600 0.71 ALDH1A1 (0.61) ALDH1A1PARP1LMNAMAPTPOLB
SCHEMBL81346 0.71 ALDH1A1 (0.61) ALDH1A1PARP1LMNAMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8664404-B2 Method for producing 3-halo-1,2-benzisothiazoles SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 2014-03-04 US claimed
EP-3880666-B1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2023-06-28 EP disclosed
EP-2554543-B1 METHOD FOR PRODUCING 3-HALO-1,2-BENZISOTHIAZOLES SUMITOMO SEIKA CHEMICALS (JP) 2015-01-21 EP disclosed
US-8802862-B2 1,2-benzisothiazol-3-one compound production method SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 2014-08-12 US disclosed
US-8664404-B2 Method for producing 3-halo-1,2-benzisothiazoles SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 2014-03-04 US disclosed
EP-2687519-A1 1,2-BENZISOTHIAZOL-3-ONE COMPOUND PRODUCTION METHOD Sumitomo Seika Chemicals CO. LTD. (JP) 2014-01-22 EP disclosed
US-20130345433-A1 1,2-BENZISOTHIAZOL-3-ONE COMPOUND PRODUCTION METHOD SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 2013-12-26 US disclosed
EP-2554543-A1 METHOD FOR PRODUCING 3-HALO-1,2-BENZISOTHIAZOLES Sumitomo Seika Chemicals Co., Ltd. (JP) 2013-02-06 EP disclosed
US-20130005983-A1 METHOD FOR PRODUCING 3-HALO-1,2-BENZISOTHIAZOLES SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 2013-01-03 US disclosed
EP-1081141-B1 Method for producing 1,2-benzisothiazol-3-ones SUMITOMO SEIKA CHEMICALS (JP) 2005-05-04 EP disclosed
US-5773626-A HALOGENATION OF A 2-(ALKYLTHIO)BENZALDEHYDE OXIME SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 1998-06-30 US disclosed
US-5744609-A REACTING AN ALKYLTHIOBENZAMIDE WITH A HALOGEN IN A HETEROGENOUS SOLVENT TO GIVE ALKYLSULFURYLBENZAMIDES INTERMEDIATES; USEFUL ANTIBACTERIAL AND ANTIFUNGAL AGENT SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 1998-04-28 US disclosed
US-5672751-A TREATMENT OF A HALOBENZAMIDE WITH AN ALKANETHIOL IN THE PRESENCE OF A PHASE TRANSFER CATALYST SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 1997-09-30 US disclosed
EP-0657438-B1 Method for producing 1,2-benzisothiazol-3-ones SUMITOMO SEIKA CHEMICALS (JP) 1997-07-30 EP disclosed
US-5633384-A FROM O-ALKYLTHIOBENZONITRILES SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 1997-05-27 US disclosed
EP-0751123-A2 Method for producing alkylsulfinylbenzamides SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 1997-01-02 EP disclosed
US-5508416-A HALOGENATING A 2-(ALKYLTHIO)BENZAMIDE, CYCLIZATION TO HETERO RING AND N-S LINKAGE SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 1996-04-16 US disclosed
EP-0702008-A2 Method for producing 1,2-benzisothiazol-3-ones SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 1996-03-20 EP disclosed
EP-0657438-A2 Method for producing alkylsulfinylbenzamides and 1,2-benzisothiazol-3-ones SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 1995-06-14 EP disclosed
US-4195023-A ELASTASE INHIBITORS, TREATMENT OF EMPHYSEMA MERCK & CO., INC. (US) 1980-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005983-A1 METHOD FOR PRODUCING 3-HALO-1,2-BENZISOTHIAZOLES NAT1, BPNT1, CBR1 ALDH1A1 88/4885PARP1 3771/4885LMNA 4381/4885
US-20130345433-A1 1,2-BENZISOTHIAZOL-3-ONE COMPOUND PRODUCTION METHOD BZW1, BZW2, NAT1 ALDH1A1 598/4885PARP1 544/4885LMNA 4633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.